| DrugRepV_0744 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Plaque assay | Decrease (50 %) | Investigational | 29765101 |
| DrugRepV_0745 | Favipiravir | Antiviral | Influenza virus | Hendra virus | Prototype | NA | Plaque assay | Decrease (50 %) | Investigational | 29765101 |
| DrugRepV_0746 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Bangladesh | NA | Plaque assay | Decrease (50 %) | Investigational | 29765101 |
| DrugRepV_0747 | Favipiravir | Antiviral | Influenza virus | Nipah virus | rNiV-Gluc-eGFP | NA | Plaque assay | Decrease (50 %) | Investigational | 29765101 |
| DrugRepV_0748 | Favipiravir | Antiviral | Influenza virus | Nipah virus | rNiV-Gluc-eGFP | NA | Cytopathic effect (CPE) assay | Decrease (4 Log (pfu/ml)) | Investigational | 29765101 |
| DrugRepV_0749 | Favipiravir | Antiviral | Influenza virus | Nipah virus | rNiV-Gluc-eGFP | NA | Real-time PCR | Decrease (10 Fold) | Investigational | 29765101 |
| DrugRepV_0750 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | NA | Increase | Investigational | 29765101 |
| DrugRepV_0751 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Real-time PCR | Decrease (20,000 / 2,000 / 500 Fold) | Investigational | 29765101 |
| DrugRepV_0752 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Immunohistochemical assay | Decrease | Investigational | 29765101 |
| DrugRepV_0753 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Survival assay | Increase | Investigational | 29765101 |
| DrugRepV_0754 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Real-time PCR | Decrease (30,000 / 300 / 100 Fold) | Investigational | 29765101 |
| DrugRepV_0755 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Immunohistochemical assay | Decrease | Investigational | 29765101 |
| DrugRepV_3598 | Brilliant Green | Antiseptic | Bacterial infections | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3599 | Gentian Violet | NA | Bacterial infection | Fungal infections (mouth (thrush) and skin) | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3600 | Gliotoxin | NA | NA | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | NA | 19889218 |
| DrugRepV_3601 | Brilliant Green | Antiseptic | Bacterial infections | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3602 | Gentian Violet | NA | Bacterial infection | Fungal infections (mouth (thrush) and skin) | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3603 | Gliotoxin | NA | NA | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | NA | 19889218 |
| DrugRepV_3604 | Brilliant Green | Antiseptic | Bacterial infections | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3605 | Gentian Violet | NA | Bacterial infection | Fungal infections (mouth (thrush) and skin) | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3606 | Gliotoxin | NA | NA | Nipah virus | NA | NA | Taqman PCR | Decrease (50 %) | NA | 19889218 |
| DrugRepV_3607 | Brilliant Green | Antiseptic | Bacterial infections | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3608 | Gentian Violet | NA | Bacterial infection | Fungal infections (mouth (thrush) and skin) | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | Approved | 19889218 |
| DrugRepV_3609 | Gliotoxin | NA | NA | Hendra virus | NA | NA | Taqman PCR | Decrease (50 %) | NA | 19889218 |
| DrugRepV_3611 | C-c3 Ado | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3612 | 5 Noraristeromycin | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3613 | DHCaA | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3614 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3615 | EICAR | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3616 | Pyrazofurin | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3617 | Carbodine | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3618 | 6-Azauridine | NA | Cancer | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3619 | Poly(I)-poly(C12U) | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3620 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3621 | 6-Azauridine | NA | Cancer | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3622 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3693 | BCX4430 | NA | Ebola virus | Nipah virus | Malaysia | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3734 | OSU-03012 | Anticancer | Brain cancer | Nipah virus | NA | NA | GFP assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_4006 | 2-APB | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4007 | A23187 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4008 | Di-Tert-Butylhydroquinone | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4009 | CA1001 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4010 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4011 | Ionomycin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4012 | Ryanodine | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4013 | Thapsigargin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4014 | Xestospongin C | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4015 | 2-APB | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4016 | A23187 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4017 | Di-Tert-Butylhydroquinone | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4018 | CA1001 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4019 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4020 | Ionomycin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4021 | Ryanodine | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4022 | Thapsigargin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4023 | Xestospongin C | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4024 | Agatoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4025 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4026 | Conotoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4027 | Gabapentin | NERVOUS SYSTEM | Epilepsy (seizure) | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4028 | Lanthanum Chloride | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4029 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4030 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4031 | Praziquantel | Antiparasitic products, Insectisides and Repellents | Schistosomiasis | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4032 | Tetrandrine | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental | 20668647 |
| DrugRepV_4033 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4034 | 5-N-ethyl isopropyl amiloride | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4035 | Amiloride | Cardiovascular agents | Hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4036 | Benzamil | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4037 | Monensin | Antibiotics | Bacterial infections | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental, Vet approved | 20668647 |
| DrugRepV_4038 | Phenytoin | Nervous System | Seizures | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Vet approved | 20668647 |
| DrugRepV_4039 | Agatoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4040 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4041 | Conotoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4042 | Gabapentin | Epilepsy | Epilepsy (seizure) | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4043 | Lanthanum Chloride | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4044 | Mibefradil | Cardiovascular agents | Angina | High blood pressure | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational, Withdrawn | 20668647 |
| DrugRepV_4045 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4046 | Praziquantel | Antiparasitic products, Insectisides and Repellents | Schistosomiasis | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4047 | Tetrandrine | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental | 20668647 |
| DrugRepV_4048 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4049 | 5-N-ethyl isopropyl amiloride | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4050 | Amiloride | Cardiovascular agents | Hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4051 | Benzamil | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4052 | Monensin | Antibiotics | Bacterial infections | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Experimental, Vet approved | 20668647 |
| DrugRepV_4053 | Phenytoin | Nervous System | Seizures | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Vet approved | 20668647 |
| DrugRepV_4054 | 7-octyl-indolactam | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4055 | Cyclosporine | Antineoplastic and Immunomodulating Agents | Immune disorders | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4056 | Gliotoxin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4057 | Oleic Acid | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4058 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4059 | PKC Inhibitor | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4060 | PMA | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4061 | Rottlerin | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4062 | U73122 | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4063 | 7-octyl-indolactam | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4064 | Cyclosporine | Immune disorders | Immune disorders | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4065 | Gliotoxin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4066 | Oleic Acid | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational, Vet approved | 20668647 |
| DrugRepV_4067 | Phenoxybenzamine | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4068 | PKC Inhibitor | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4069 | PMA | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4070 | Rottlerin | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4071 | U73122 | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | NA | 20668647 |
| DrugRepV_4072 | 25-OH-cholecalciferol | NA | NA | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Nutraceutical | 20668647 |
| DrugRepV_4073 | 4-OH-tamoxifen | NA | Breast cancer | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4074 | Arg-vasopressin | NA | Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4075 | Bradykinin | NA | Hypertension and Diabetes Type 2 | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4076 | Caffeine | Nervous System | Fatigue, orthostatic hypotension | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4077 | Cholecalciferol | NA | Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4078 | Clotrimazole | Dermatologicals | Fungal infections | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4079 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |
| DrugRepV_4080 | 25-OH-cholecalciferol | NA | NA | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Nutraceutical | 20668647 |
| DrugRepV_4081 | 4-OH-tamoxifen | NA | Breast cancer | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4082 | Arg-vasopressin | NA | Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4083 | Bradykinin | NA | Hypertension and Diabetes Type 3 | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Investigational | 20668647 |
| DrugRepV_4084 | Caffeine | Nervous System | Fatigue, orthostatic hypotension | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4085 | Cholecalciferol | NA | Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4086 | Clotrimazole | Dermatologicals | Fungal infections | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4087 | Propranolol | Cardiovascular agents | Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved, Investigational | 20668647 |
| DrugRepV_4371 | N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (24.79 %) | NA | 24501399 |
| DrugRepV_4372 | N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (31.07 %) | NA | 24501399 |
| DrugRepV_4373 | 9H-carbazol-3-amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (8.2 %) | NA | 24501399 |
| DrugRepV_4374 | 7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.87 %) | NA | 24501399 |
| DrugRepV_4375 | N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.67 %) | NA | 24501399 |
| DrugRepV_4376 | tris[4-(dimethylamino)phenyl]methanol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (108.4 %) | NA | 24501399 |
| DrugRepV_4377 | 6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (39.17 %) | NA | 24501399 |
| DrugRepV_4378 | 1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (5.24 %) | NA | 24501399 |
| DrugRepV_4379 | 2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.7 %) | NA | 24501399 |
| DrugRepV_4380 | N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (40.4 %) | NA | 24501399 |
| DrugRepV_4381 | 4-{[(5-methyl-2-thienyl)methyl]amino}phenol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-14.4 %) | NA | 24501399 |
| DrugRepV_4382 | N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-7.77 %) | NA | 24501399 |
| DrugRepV_4383 | N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (0.34 %) | NA | 24501399 |
| DrugRepV_4384 | 2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-9.26 %) | NA | 24501399 |
| DrugRepV_4385 | N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (73.49 %) | NA | 24501399 |
| DrugRepV_4386 | N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-4.08 %) | NA | 24501399 |
| DrugRepV_4387 | 4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (7.92 %) | NA | 24501399 |
| DrugRepV_4388 | N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (42.12 %) | NA | 24501399 |
| DrugRepV_4389 | N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (32.88 %) | NA | 24501399 |
| DrugRepV_4390 | N-(3-chlorophenyl)-N-(4-cyanophenyl)urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (24.49 %) | NA | 24501399 |
| DrugRepV_4391 | N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (0.86 %) | NA | 24501399 |
| DrugRepV_4392 | N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (6.5 %) | NA | 24501399 |
| DrugRepV_4393 | 4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-7.5 %) | NA | 24501399 |
| DrugRepV_4394 | 1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (35.73 %) | NA | 24501399 |
| DrugRepV_4395 | 2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.85 %) | NA | 24501399 |
| DrugRepV_4396 | N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.33 %) | NA | 24501399 |
| DrugRepV_4397 | 2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (22.44 %) | NA | 24501399 |
| DrugRepV_4398 | N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (37.22 %) | NA | 24501399 |
| DrugRepV_4399 | 4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (33.41 %) | NA | 24501399 |
| DrugRepV_4400 | N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (7.38 %) | NA | 24501399 |
| DrugRepV_4401 | 3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.01 %) | NA | 24501399 |
| DrugRepV_4402 | methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (90.92 %) | NA | 24501399 |
| DrugRepV_4403 | N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (12.1 %) | NA | 24501399 |
| DrugRepV_4404 | N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (21.93 %) | NA | 24501399 |
| DrugRepV_4405 | (1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-8.72 %) | NA | 24501399 |
| DrugRepV_4406 | 4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (17.7 %) | NA | 24501399 |
| DrugRepV_4407 | N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (23.22 %) | NA | 24501399 |
| DrugRepV_4408 | 3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (23.55 %) | NA | 24501399 |
| DrugRepV_4409 | 5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.55 %) | NA | 24501399 |
| DrugRepV_4410 | 6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (32.65 %) | NA | 24501399 |
| DrugRepV_4411 | 2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.23 %) | NA | 24501399 |
| DrugRepV_4412 | N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (25.12 %) | NA | 24501399 |
| DrugRepV_4413 | 4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-11.51 %) | NA | 24501399 |
| DrugRepV_4414 | 2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (5.7 %) | NA | 24501399 |
| DrugRepV_4415 | 5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-10.47 %) | NA | 24501399 |
| DrugRepV_4416 | 2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-2.95 %) | NA | 24501399 |
| DrugRepV_4417 | 2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-9.09 %) | NA | 24501399 |
| DrugRepV_4418 | N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-0.72 %) | NA | 24501399 |
| DrugRepV_4419 | 8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (-10.37 %) | NA | 24501399 |
| DrugRepV_4420 | N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide | NA | NA | Hendra virus | F0, amino acids 105 to 114 | NA | CatL-Peptide cleavage | Decrease (3.26 %) | NA | 24501399 |
| DrugRepV_7103 | Chebulagic Acid | NA | Immunosuppressive and hepatoprotective | Measles virus | IC323 |  | EGFP assay | Decrease (50 %) | NA | 23924316 |
| DrugRepV_7104 | Punicalagin | Plant pigment | NA | Measles virus | IC323 | | EGFP assay | Decrease (50 %) | NA | 23924316 |
| DrugRepV_7105 | Chebulagic Acid | NA | Immunosuppressive and hepatoprotective | Measles virus | IC323 | | EGFP assay | Decrease (80 %) | NA | 23924316 |
| DrugRepV_7106 | Punicalagin | Plant pigment | NA | Measles virus | IC323 | | EGFP assay | Decrease (80 %) | NA | 23924316 |
| DrugRepV_7238 | BCX4430 | NA | Ebola virus | Measles virus | Chicago | | RT-PCR | Decrease (50 %) | Investigational | 24590073 |